Israel-based FoodTech start-up BioBetter has opened its first food-grade pilot facility to accelerate the production of key growth factors for the cultivated meat industry. The company has pioneered a unique protein manufacturing platform for producing growth factors (GFs) using tobacco plants as self-sustained, animal-free bioreactors.

Solving bottleneck challenges

Helping cultivated meat companies offer affordable and accessible products to consumers, BioBetter is revolutionizing the future of cellular agriculture with its innovative molecular farming-based production platform. Currently, cultivated meat production processes are relatively expensive, making it a challenge to
scale up and reach price parity with animal-based counterparts.

“Cultivated meat is still very expensive in comparison to conventional meat and the key is to reduce the growth medium costs to a minimum,” explained Amit Yaari, Ph.D., CEO of BioBetter. “Our target is to reduce the production cost of growth factors, including insulin, a key part of the growth medium, to $1 per gram which is a 100-fold less than the going rate today.”

The start-up already has achieved five impressive milestones  in the past year:

1. Production scale-up/building pilot plan
2. Commercial scale cultivation of insulin- and FGF-expressing tobacco plants
3. Reaching GF expression levels that enable a significant reduction of production costs
4. Significant regulatory progresses and advances with the Israel Ministry of Health
5. Collaboration with leading cultivated meat companies

Plant bioreactor technology

BioBetter discovered a new purpose for the traditionally shunned tobacco plants, transforming them into bioreactors for the production of GFs. These GFs play a key role in the proliferation and differentiation of cultured meat cells, allowing for the formation of authentic and well-structured muscle tissue.

Designed for both environmental safety and efficiency, these bioreactors will be grown in a large-scale, net house cultivation system. The plants are carefully engineered to prevent the escape of any transgenic material. They are induced to express growth factors only when chemically triggered, and the company exclusively uses non-food, non-feed tobacco plants to eliminate any risk of inadvertent consumption or cross-contamination of food crops.

Sustainability at the core

“Our holistic approach not only underscores our commitment to safety and environmental responsibility but also streamlines regulatory processes,” said Dana Yarden, M.D., co-founder of BioBetter. “Our commitment to sustainability shines through in every facet of our operations. We plan to use recycled and low-quality water for irrigation, minimize nitrogen fertilizer use, and reduce emissions and environmental impact.”

The newly established pilot plant has the capacity to process 100kg of tobacco plant-derived GFs daily. Constructed in adherence to the highest quality standards, the facility meets all regulatory requirements for production of food-grade growth factors, including FGF2 and insulin. It currently is progressing through essential stages of securing approval from the Ministry of Health for food manufacturing licensing. The company is committed to scalability, adhering to ISO2200 and HACCP standards.

“We more than doubled our workforce from 23 to 50 workers to advance all aspects of production, cultivation, and R&D,” said Yaari. “We stimulate the commercial aspirations of cultivated meat start-ups and the pilot plant signifies a substantial step toward the company’s next growth stage in 2025: the capacity for processing 25 tonnes of leaves daily, reaching commercial production of five tonnes annually by the end of 2025.”

A growing future

BioBetter also made breakthroughs in the cultivation of bovine insulin-expressing plants. Several thousand square metres of FGF2-expressing tobacco plants are already thriving in northern Israel. It’s the first time growth factor sources have been successfully planted in large net-houses, in four locations, and with a fruitful harvest obtained in its first season. Plans are underway to cultivate more FGF2 and insulin-expressing plants, wit commercial roll-out projected for 2024.

“Over the past year, our outreach and collaborations expanded considerably,” said Yarden. “We’ve shared GF samples with numerous cultivated meat companies and cell media producers worldwide and received promising proof-of-concept results for both our FGF2 and insulin from several companies and academic laboratories.”

The $250 million global cultivated meat sector is poised for substantial growth, yet its realization hinges upon a significant supply of growth factors.

“The most significant challenge of the cultivated meat industry is to produce and scale up at the right cost,” said Aviv Oren, Director of Business Engagement and Innovation, the Good Food Institute, Israel. “Biobetter’s technology, which is based on molecular farming of food-grade growth factors in the required quantities and costs for industrial production, is a pivotal addition that has the potential to accelerate this industry.”

In 2022, BioBetter secured US$10 million in A-round investment led by Jerusalem Venture Partners (JVP). The company also is an active member of the Israeli Cultivated Meat Consortium, which unites academic institutions, large companies, and start-ups to collaboratively advance the field of cultivated meat.

www.biobetter.bio